12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GSK573719/vilanterol: Phase IIIa data

A 24-week, double-blind, international Phase IIIa trial in 846 COPD patients showed that once-daily 62.5/25 and 125/25 µg doses of GSK573719/vilanterol each met the co-primary endpoints of improving trough FEV1 from baseline to the end of treatment on day 169 vs. 25 µg vilanterol alone and Spiriva HandiHaler tiotropium. Specifically, both doses of GSK573719/vilanterol led to control-adjusted improvements in trough FEV1 of 88-90 mL in each arm (p<0.001 for...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >